Drug Resistance in Diffuse Large B-Cell Lymphoma

Seminars in Hematology

Volumn 43, Issue 4, 2006, Pages 230-239

  Wilson, Wyndham H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DEXVERAPAMIL; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; FLAVOPIRIDOL; GELDANAMYCIN; IFOSFAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE; OBLIMERSEN; PREDNISONE; PROTEIN BCL 2; QUININE; RITUXIMAB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CARDIOMYOPATHY; CELL CYCLE; CELL DIFFERENTIATION; CLINICAL TRIAL; DIFFUSE LARGE B CELL LYMPHOMA; DRUG MECHANISM; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; LUNG DISEASE; MICROARRAY ANALYSIS; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMATITIS; TRANSLATION INITIATION;

APOPTOSIS; CELL CYCLE; CLINICAL TRIALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOKINETICS; TREATMENT FAILURE;

EID: 33749348834     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.07.005     Document Type: Article

References (57)

1. Wilson W.H., Bates S.E., Fojo A., Bryant G., Zhan Z., Regis J., et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13 (1995) 1995-2004
2. Gaynor E.R., Unger J.M., Miller T.P., Grogan T.M., White Jr. L.A., Mills G.M., et al. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group study. J Clin Oncol 19 (2001) 750-755
3. Lee W.P., Lee C.L., and Lin H.C. Glutathione S-transferase and glutathione peroxidase are essential in the early stage of Adriamycin resistance before P-glycoprotein overexpression in HOB1 lymphoma cells. Cancer Chemother Pharmacol 38 (1996) 45-51
4. Alenzi F.Q., Wyse R.K., and Altamimi W.G. Apoptosis as a tool for therapeutic agents in haematological diseases. Expert Opin Biol Ther 4 (2004) 407-420
5. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., and Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362 (1993) 847-849
6. Goldie J.H., and Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63 (1979) 1727-1733
7. Harris C.C., and Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329 (1993) 1318-1327
8. Longo D.L., DeVita Jr. V.T., Duffey P.L., Wesley M.N., Ihde D.C., Hubbard S., et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol 9 (1991) 25-38
9. Fisher R.I., Gaynor E.R., Dahlberg S., Oken M.M., Grogan T.M., Mize E.M., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 (1993) 1002-1006
10. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., and Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 84 (1987) 265-269
11. Lai G.M., Chen Y.N., Mickley L.A., Fojo A.T., and Bates S.E. P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 49 (1991) 696-703
12. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 57 (1999) 727-741
13. Lynch A., Harvey J., Aylott M., Nicholas E., Burman M., Siddiqui A., et al. Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity. Mutagenesis 18 (2003) 345-353
14. Cole D.E., Balis F.M., Lowe E.S., et al. Pharmacokinetics (pk) and tolerance of doxorubicin (dox) and etoposide (etop) during treatment of aggressive B-cell lymphomas indicate doses need not be routinely reduced for hepatic dysfunction. Proc Am Soc Clin Oncol 24 (2005) (abstr)
15. Kwak L.W., Halpern J., Olshen R.A., and Horning S.J. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 8 (1990) 963-977
16. Meyer R.M., Quirt I.C., Skillings J.R., Cripps M.C., Bramwell V.H., Weinerman B.H., et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 1770-1776
17. Kaiser U., Uebelacker I., Abel U., Birkmen J., Trumper L., Schmalenberg H., et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol 20 (2002) 4413-4419
18. Haioun C., Lepage E., Gisselbrecht C., Salles G., Coiffier B., Brice P., et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol-A groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 18 (2000) 3025-3030
19. Wilson W.H., Grossbard M.L., Pittaluga S., Cole D., Pearson D., Drbohlav N., et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood 99 (2002) 2685-2693
20. Lowe E., Balis F.M., Cole D.E., Goodspeed W., Drbohlav N., and Wilson W.H. Pharmacokinetics of doxorubicin and doxorubicinol in dose-adjusted EPOCH infusional chemotherapy. Am Assoc Cancer Res (2002)
21. Skipper H.E., Schabel Jr. F.M., and Wilcox W.S. Experimental evaluation of potential anticancer agents. Xiii. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35 (1964) 1-111
22. Dave S.S., Fu K., Wright G., Lam L., Grenier T.C., Weisenberger D.D., et al. Gene expression distinguishes Burkitt lymphoma from other aggressive lymphomas and identifies patients who are highly curable with intensive chemotherapeutic regimens. ASH Annual Meeting Abstracts 106 (2000) 415
23. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 1937-1947
24. Miller T.P., Grogan T.M., Dahlberg S., Spier C.M., Braziel R.M., Banks P.M., et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 83 (1994) 1460-1466
25. Pfreundschuh M., Trümper L., Kloess M., et al. 2-weekly vs. 3-weekly CHOP with and without etoposide in for patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL): Results of the completed NHL-B-2 trial of the DSHNHL. Blood 99 (2002) (abstr 3060)
26. Pfreundschuh M., Trümper L., Schmits R., et al. 2-weekly vs. 3-weekly CHOP with and without etoposide in young patients with low-risk (low LDH) aggressive non-Hodgkin's lymphoma: Results of the completed NHL-B-1 trial of the DSHNHL. Blood 99 (2002) (abstr 340)
27. + diffuse large B-cell lymphoma (DLBCL)-CALGB 50103. Proc Am Soc Clin Oncol 24 (2005) (abstr)
28. Wilson W.H., Teruya-Feldstein J., Fest T., Harris C., Steinberg S.M., Jaffe E.S., et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89 (1997) 601-609
29. Ichikawa A., Kinoshita T., Watanabe T., Kato H., Nagai H., Tsushita K., et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337 (1997) 529-534
30. Hans C.P., Weisenburger D.D., Greiner T.C., Chan W.C., Aoun P., Cochran G., et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 18 (2005) 1377-1384
31. Filipits M., Jaeger U., Pohl G., Stranzl T., Simonitsch I., Kaider A., et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 8 (2002) 729-733
32. Paik J.H., Jeon Y.K., Park S.S., Kim Y.A., Kim J.E., Huh J., et al. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas. Histopathology 47 (2005) 281-291
33. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24 (2006) 1770-1783
34. O'Connor O.A. Developing new drugs for the treatment of lymphoma. Eur J Haematol suppl (2005) 150-158
35. Sachs L., and Lotem J. Control of programmed cell death in normal and leukemic cells: New implications for therapy. Blood 82 (1993) 15-21
36. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., and Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348 (1990) 334-336
37. Gascoyne R.D., Adomat S.A., Krajewski S., Krajewska M., Horsman D.E., Tolcher A.W., et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90 (1997) 244-251
38. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
39. Mounier N., Briere J., Gisselbrecht C., Emile J.F., Lederlin P., Sebban C., et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101 (2003) 4279-4284
40. Wilson W., Pittaluga S., O'Connor P., Hegde U., Drbohlav N., Janik J., et al. Rituximab may overcome BCL-2-associated chemotherapy resistance in untreated diffuse large B-cell lymphomas. Proc Am Soc Hematol 99 (2001)
41. Winter J.N., Weller E.A., Horning S.J., Krajewska M., Variakojis D., Habermann T.M., et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study. Blood 2005-2010 (2006)
42. Dunleavy K., Pittaluga S., Janik J., Grant N., Steinberg S., Staudt L., et al. Primary mediastinal large B-cell lymphoma (PMBL) outcome is significantly improved by the addition of rituximab to dose adjusted (DA)-EPOCH and overcomes the need for radiation. ASH Annual Meeting Abstracts 106 (2005) 623 (abstr)
43. Rosenwald A., Wright G., Leroy K., Yu X., Gaulard P., Gascoyne R.D., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198 (2003) 851-862
44. Jazirehi A.R., Huerta-Yepez S., Cheng G., and Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 65 (2005) 264-276
45. Davis R.E., Brown K.D., Siebenlist U., and Staudt L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194 (2001) 1861-1874
46. Dunleavy K., Janik J., Gea-Banacloche J., Shovlin M., White T., Goldschmidt N., et al. Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma. ASH Annual Meeting Abstracts 104 (2004) 1385 (abstr)
47. Wilson W.H., Sorbara L., Figg W.D., Mont E.K., Sausville E., Warren K.E., et al. Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: Presentation of a novel therapeutic paradigm. Clin Cancer Res 6 (2000) 415-421
48. Georgakis G.V., and Younes A. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol 1 (2005) 273-281
49. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
50. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
51. Dalla-Favera R., Migliazza A., Chang C.C., Niu H., Pasqualucci L., Butler M., et al. Molecular pathogenesis of B cell malignancy: The role of BCL-6. Curr Top Microbiol Immunol 246 (1999) 257-263
52. Mittrucker H.W., Matsuyama T., Grossman A., Kundig T.M., Potter J., Shahinian A., et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275 (1997) 540-543
53. Shipp M.A., Ross K.N., Tamayo P., Weng A.P., Kutok J.L., Aguiar R.C., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8 (2002) 68-74
54. Leitges M., Schmedt C., Guinamard R., Davoust J., Schaal S., Stabel S., et al. Immunodeficiency in protein kinase cbeta-deficient mice. Science 273 (1996) 788-791
55. Savage K.J., Monti S., Kutok J.L., Cattoretti G., Neuberg D., de Leval L., et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin's lymphoma. Blood 2003-2006 (2003)
56. Hryniuk W., and Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2 (1984) 1281-1288
57. Wilson W.H., et al. Dose-adjusted EPOCH-rituximab in untreated diffuse large B-cell lymphoma: Benefit of rituximab appears restricted to tumors harboring anti-apoptotic mechanisms. ASH Annual Meeting Abstracts 103 (2003) 356 (abstr)